COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
Ivermectin study #13 of 63
9/24 Late treatment study
Khan et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.08.007 (Letter)
Ivermectin treatment may improve the prognosis of patients with COVID-19
Source   PDF   Share   Tweet
Retrospective 115 ivermectin patients and 133 control patients showing significantly lower death and faster viral clearance.
Some potential issues and the authors' response can be found in [1, 2].

Khan et al., 9/24/2020, retrospective, Bangladesh, South Asia, preprint, median age 35.0, 8 authors, dosage 12mg single dose.
risk of death, 87.0% lower, RR 0.13, p < 0.05, treatment 1 of 115 (0.9%), control 9 of 133 (6.8%).
time to viral-, 73.3% lower, relative time 0.27, p < 0.001, treatment 115, control 133.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 63 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit